J Infect Dis: Recombinant bubble-ventitis virus - immune-to-immune, heterogeneous and safety analysis of the Zaire Ebola virus envelope glycoprotein vaccine.

!---- This dual-blind study assessed the immunogenicity, batch consistency and safety of the recombinant bubbly oral itisvirus-Zaire Ebola virus-Zaire Endomeleta Vaccine (rVSV G-ZEBOV-GP)1197 healthy adults were randomly 2:2:2:2:1 receiving 3 consistency batches of rVSV G-ZEBOV-GP (2 x 107 plaque formation units (pfu), high dose 1 x 108 pfu or one placeboAntibody response sat before/after vaccination (28 days, 6 months; 12, 18 and 24 months) in a subset of sn s566The results showed that the ZEBOV-GP enzyme-linked immunosorption test (ELISA) geometric average titness (GMTs) increased by 28 days after vaccination in all rVSV-G-ZEBOV-GP groups and continued for 24 months3 production batches showed the same immunogenicity at 28 daysIn all rVSV-G-ZEBOV-GP groups, neutralizing antibody GMTs increased within 28 days, peaked within 18 months and did not decrease within 24 monthsAt 28 days, the serum response of 94% of the recipients (ZEBOV-GP ELISA, increased by 2 times, titer is 200 EU/mL), and at 24 months the reaction of the recipients was sustained by 91%A woman's history of gender and arthritis is a potentially dangerous factor for post-vaccination arthritisIn summary, the results show that the immune response to rVSV G-ZEBOV-GP lasts for 24 monthsImmunogenicity and safety results support the continued development of rVSV G-ZEBOV-GP